关于sevoflurane诱导的认知功能障碍的新视角:神经SIRPα和微质突触重塑的影响
Wei Du1, Xiaomin Zhang1, Songze Li1
1Department of Anesthesiology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, China.
ACS chemical neuroscience
|December 7, 2024
概括
神经神经SIRPα (信号调节蛋白α) 和微质突触重塑保护新生小鼠免受sevoflurane诱导的认知功能障碍. 提高SIRPα功能可以改善这些障碍.
科学领域:
- 神经科学是一个神经科学.
- 发展生物学 发展生物学
- 麻醉学 麻醉学
背景情况:
- 黄麻醉在新生儿中被广泛使用,但其对认知功能的长期影响仍然令人担忧.
- 微质在突触重塑和神经元发育中起着至关重要的作用,这些过程可能对麻醉剂很脆弱.
- 了解麻醉引起的认知障碍背后的分子机制对于开发神经保护策略至关重要.
研究的目的:
- 研究神经SIRPα和微质突触重塑在新生小鼠中sevoflurane诱导的认知功能障碍中的作用.
- 探索增强神经元SIRPα功能的治疗潜力,以抵消sevoflurane的不良影响.
- 在麻醉剂暴露的背景下阐明SIRPα表达和微质活性之间的关系.
主要方法:
- 新生小鼠被暴露在sevoflurane中,随后进行行为测试 (社会认知,运动协调).
- 在皮层细胞上进行了单细胞转录组测序和SCENIC分析.
- 通过lentivirus介导的神经SIRPα的过度表达被用来评估其对微质形态,突触功能和认知结果的影响.
主要成果:
- 暴露于赛沃兰诱导了社会认知缺陷,但没有影响运动协调.
- 转录组分析显示,sevoflurane抑制了微质非突触突触修饰.
- 神经元SIRPα的过度表达改善了微质功能,促进了神经元发育,并挽救了认知障碍,与IRF8表达相关.
结论:
- 神经SIRPα和微质突触重塑是sevoflurane诱导的认知功能障碍中的关键参与者.
- 准神经SIRPα提供了一个有前途的治疗策略,以减轻麻醉引起的神经发育和认知缺陷.
- 这项研究为麻醉神经毒性的机制以及干预的潜在途径提供了新的见解.
相关概念视频
01:09Synaptic Signaling
Neurons communicate at synapses, or junctions, to excite or inhibit the activity of other neurons or target cells, such as muscles. Synapses may be chemical or electrical.
Most synapses are chemical, meaning an electrical impulse or action potential spurs the release of chemical messengers called neurotransmitters. The neuron sending the signal is called the presynaptic neuron, and the neuron receiving the signal is the postsynaptic neuron.
The presynaptic neuron fires an action potential that...
Most synapses are chemical, meaning an electrical impulse or action potential spurs the release of chemical messengers called neurotransmitters. The neuron sending the signal is called the presynaptic neuron, and the neuron receiving the signal is the postsynaptic neuron.
The presynaptic neuron fires an action potential that...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...